Cargando…

Gamma Knife Radiosurgery For Brain Vascular Malformations: Current Evidence And Future Tasks

Gamma Knife radiosurgery (GKRS) has long been used for treating brain vascular malformations, including arteriovenous malformations (AVMs), dural arteriovenous fistulas (DAVFs), and cavernous malformations (CMs). Herein, current evidence and controversies regarding the role of stereotactic radiosurg...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasegawa, Hirotaka, Yamamoto, Masaaki, Shin, Masahiro, Barfod, Bierta E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874113/
https://www.ncbi.nlm.nih.gov/pubmed/31819462
http://dx.doi.org/10.2147/TCRM.S200813
_version_ 1783472776768651264
author Hasegawa, Hirotaka
Yamamoto, Masaaki
Shin, Masahiro
Barfod, Bierta E
author_facet Hasegawa, Hirotaka
Yamamoto, Masaaki
Shin, Masahiro
Barfod, Bierta E
author_sort Hasegawa, Hirotaka
collection PubMed
description Gamma Knife radiosurgery (GKRS) has long been used for treating brain vascular malformations, including arteriovenous malformations (AVMs), dural arteriovenous fistulas (DAVFs), and cavernous malformations (CMs). Herein, current evidence and controversies regarding the role of stereotactic radiosurgery for vascular malformations are described. 1) It has already been established that GKRS achieves 70–85% obliteration rates after a 3–5-year latency period for small to medium-sized AVMs. However, late radiation-induced adverse events (RAEs) including cyst formation, encapsulated hematoma, and tumorigenesis have recently been recognized, and the associated risks, clinical courses, and outcomes are under investigation. SRS-based therapeutic strategies for relatively large AVMs, including staged GKRS and a combination of GKRS and embolization, continue to be developed, though their advantages and disadvantages warrant further investigation. The role of GKRS in managing unruptured AVMs remains controversial since a prospective trial showed no benefit of treatment, necessitating further consideration of this issue. 2) Regarding DAVFs, GKRS achieves 41–90% obliteration rates at the second post-GKRS year with a hemorrhage rate below 5%. Debate continues as to whether GKRS might serve as a first-line solo therapeutic modality given its latency period. Although the post-GKRS outcomes are thought to differ among lesion locations, further outcome analyses regarding DAVF locations are required. 3) GKRS is generally accepted as an alternative for small or medium-sized CMs in which surgery is considered to be too risky. The reported hemorrhage rates ranged from 0.5–5% after GKRS. Higher dose treatments (>15 Gy) were performed during the learning curve, while, with the current standard treatment, a dose range of 12–15 Gy is generally selected, and has resulted in acceptable complication rates (< 5%). Nevertheless, further elucidation of long-term outcomes is essential.
format Online
Article
Text
id pubmed-6874113
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-68741132019-12-09 Gamma Knife Radiosurgery For Brain Vascular Malformations: Current Evidence And Future Tasks Hasegawa, Hirotaka Yamamoto, Masaaki Shin, Masahiro Barfod, Bierta E Ther Clin Risk Manag Review Gamma Knife radiosurgery (GKRS) has long been used for treating brain vascular malformations, including arteriovenous malformations (AVMs), dural arteriovenous fistulas (DAVFs), and cavernous malformations (CMs). Herein, current evidence and controversies regarding the role of stereotactic radiosurgery for vascular malformations are described. 1) It has already been established that GKRS achieves 70–85% obliteration rates after a 3–5-year latency period for small to medium-sized AVMs. However, late radiation-induced adverse events (RAEs) including cyst formation, encapsulated hematoma, and tumorigenesis have recently been recognized, and the associated risks, clinical courses, and outcomes are under investigation. SRS-based therapeutic strategies for relatively large AVMs, including staged GKRS and a combination of GKRS and embolization, continue to be developed, though their advantages and disadvantages warrant further investigation. The role of GKRS in managing unruptured AVMs remains controversial since a prospective trial showed no benefit of treatment, necessitating further consideration of this issue. 2) Regarding DAVFs, GKRS achieves 41–90% obliteration rates at the second post-GKRS year with a hemorrhage rate below 5%. Debate continues as to whether GKRS might serve as a first-line solo therapeutic modality given its latency period. Although the post-GKRS outcomes are thought to differ among lesion locations, further outcome analyses regarding DAVF locations are required. 3) GKRS is generally accepted as an alternative for small or medium-sized CMs in which surgery is considered to be too risky. The reported hemorrhage rates ranged from 0.5–5% after GKRS. Higher dose treatments (>15 Gy) were performed during the learning curve, while, with the current standard treatment, a dose range of 12–15 Gy is generally selected, and has resulted in acceptable complication rates (< 5%). Nevertheless, further elucidation of long-term outcomes is essential. Dove 2019-11-18 /pmc/articles/PMC6874113/ /pubmed/31819462 http://dx.doi.org/10.2147/TCRM.S200813 Text en © 2019 Hasegawa et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Hasegawa, Hirotaka
Yamamoto, Masaaki
Shin, Masahiro
Barfod, Bierta E
Gamma Knife Radiosurgery For Brain Vascular Malformations: Current Evidence And Future Tasks
title Gamma Knife Radiosurgery For Brain Vascular Malformations: Current Evidence And Future Tasks
title_full Gamma Knife Radiosurgery For Brain Vascular Malformations: Current Evidence And Future Tasks
title_fullStr Gamma Knife Radiosurgery For Brain Vascular Malformations: Current Evidence And Future Tasks
title_full_unstemmed Gamma Knife Radiosurgery For Brain Vascular Malformations: Current Evidence And Future Tasks
title_short Gamma Knife Radiosurgery For Brain Vascular Malformations: Current Evidence And Future Tasks
title_sort gamma knife radiosurgery for brain vascular malformations: current evidence and future tasks
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874113/
https://www.ncbi.nlm.nih.gov/pubmed/31819462
http://dx.doi.org/10.2147/TCRM.S200813
work_keys_str_mv AT hasegawahirotaka gammakniferadiosurgeryforbrainvascularmalformationscurrentevidenceandfuturetasks
AT yamamotomasaaki gammakniferadiosurgeryforbrainvascularmalformationscurrentevidenceandfuturetasks
AT shinmasahiro gammakniferadiosurgeryforbrainvascularmalformationscurrentevidenceandfuturetasks
AT barfodbiertae gammakniferadiosurgeryforbrainvascularmalformationscurrentevidenceandfuturetasks